systhiperСистемные гипертензииSystemic Hypertension2075-082X2542-2189LLC «ИнтерМедсервис»systhiper-433Research ArticleМЕТАБОЛИЧЕСКИЕ НАРУШЕНИЯ / METABOLIC DISTURBANCESЛечение артериальной гипертензии у пациентов с избыточной массой телаTreatment of hypertension in overweight patientsКукесВ. Г.KukesV. G.noemail@neicon.ruАникинГ. С.AnikinG. S.medi321@mail.ruАндреевскаяЕ. М.AndreevskayaE. M.noemail@neicon.ruАшурковаЕ. А.AshurkovaE. A.noemail@neicon.ruГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава РоссииРоссияI.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian FederationRussian FederationГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава России; ФГБУ Поликлиника №3 Управления делами Президента РФРоссияI.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation; Out-Patient Clinic №3 of Administration of the President of Russian FederationRussian FederationФГБУ Поликлиника №3 Управления делами Президента РФРоссияOut-Patient Clinic №3 of Administration of the President of Russian FederationRussian Federation2015231220221234649Copyright © Кукес В.Г., Аникин Г.С., Андреевская Е.М., Ашуркова Е.А., 20222022Кукес В.Г., Аникин Г.С., Андреевская Е.М., Ашуркова Е.А.Kukes V.G., Anikin G.S., Andreevskaya E.M., Ashurkova E.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.syst-hypertension.ru/jour/article/view/433

При лечении артериальной гипертензии у пациентов с избыточной массой тела целью является не только нормализация артериального давления, но и улучшение показателей эндотелиальной функции, снижение инсулинорезистентности, нормализация показателей липидного обмена. Одни из препаратов, обладающие широкими терапевтическими возможностями и большой доказательной базой, - агонисты I1-имидазолиновых рецепторов, которые могут назначаться как в монотерапии, так и в составе комбинированной терапии лицам с избыточной массой тела.

The aim of the treatment of hypertension in patients with overweight is not only normalization of blood pressure, but also improvement of endothelial function, reduction of insulin resistance and lipid metabolism. Some of the drugs with a broad therapeutic spectrum and huge evidential base, - I1-imidazoline-receptor agonists can be applied in both monotherapy and as a part of the combined therapy in overweight patients.

артериальная гипертензияизбыточная масса теламоксонидинФизиотензarterial hypertensionoverweightmoxonidinePhysiotensReferencesKotseva K et al. EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol 2015.Kotseva K et al. EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol 2015.Åkesson A et al. Low-Risk Diet and Lifestyle Habits in the Primary Prevention of Myocardial Infarction in MenA Population-Based Prospective Cohort Study J Am Coll Cardiol 2014; 64 (13): 1299-306.Åkesson A et al. Low-Risk Diet and Lifestyle Habits in the Primary Prevention of Myocardial Infarction in MenA Population-Based Prospective Cohort Study J Am Coll Cardiol 2014; 64 (13): 1299-306.Чазова И.Е., Жернакова Ю.В., Ощепкова Е.В. и др. Распространенность факторов риска сердечно - сосудистых заболеваний в российской популяции больных артериальной гипертонией. Кардиология. 2014; 10: 4-12.Чазова И.Е., Жернакова Ю.В., Ощепкова Е.В. и др. Распространенность факторов риска сердечно - сосудистых заболеваний в российской популяции больных артериальной гипертонией. Кардиология. 2014; 10: 4-12.Красильникова Е.И., Баранова Е.И., Благосклонная Я.В. и др. Терапия артериальной гипертензии у больных с метаболическим синдромом. Справ. поликлин. врача. 2011; 9: 23-7.Красильникова Е.И., Баранова Е.И., Благосклонная Я.В. и др. Терапия артериальной гипертензии у больных с метаболическим синдромом. Справ. поликлин. врача. 2011; 9: 23-7.Bruyndonckx L et al. Diet, exercise, and endothelial function in obese adolescents. Pediatrics 2015; 135 (3): e653-61.Bruyndonckx L et al. Diet, exercise, and endothelial function in obese adolescents. Pediatrics 2015; 135 (3): e653-61.Walther G. Metabolic syndrome individuals with and without type 2 diabetes mellitus present generalized vascular dysfunction: cross - sectional study. Arterioscler Thromb Vasc Biol 2015; 35 (4): 1022-9.Walther G. Metabolic syndrome individuals with and without type 2 diabetes mellitus present generalized vascular dysfunction: cross - sectional study. Arterioscler Thromb Vasc Biol 2015; 35 (4): 1022-9.Van Sloten T.T Endothelial dysfunction plays a key role in increasing cardiovascular risk in type 2 diabetes: the Hoorn study. Hypertension 2014; 64 (6): 1299-305.Van Sloten T.T Endothelial dysfunction plays a key role in increasing cardiovascular risk in type 2 diabetes: the Hoorn study. Hypertension 2014; 64 (6): 1299-305.Topal E et al. The effect of moxonidine on endothelial dysfunction in metabolic syndrome. Am J Cardiovasc Drugs 2006; 6 (5): 343-8.Topal E et al. The effect of moxonidine on endothelial dysfunction in metabolic syndrome. Am J Cardiovasc Drugs 2006; 6 (5): 343-8.Jacob S et al. Effects of moxonidine vs. metoprolol on blood pressure and metabolic control in hypertensive subjects with type 2 diabetes. Exp Clin Endocrinol Diabetes 2004; 112 (6): 315-22.Jacob S et al. Effects of moxonidine vs. metoprolol on blood pressure and metabolic control in hypertensive subjects with type 2 diabetes. Exp Clin Endocrinol Diabetes 2004; 112 (6): 315-22.Theodor R, Weimann H.J, Weber W et al. Absolute bio - availability of moxonidine. Eur J Drug Metab Pharmacokinet 1991; 16 (2): 153-9.Theodor R, Weimann H.J, Weber W et al. Absolute bio - availability of moxonidine. Eur J Drug Metab Pharmacokinet 1991; 16 (2): 153-9.Mitrovic V, Patyna W, Hütting J et al. Hemodinamic and neurohumoral effect of moxonidine in patients with essential hypertension. Cardiovase Drugs Ther 1991; 5: 967-72.Mitrovic V, Patyna W, Hütting J et al. Hemodinamic and neurohumoral effect of moxonidine in patients with essential hypertension. Cardiovase Drugs Ther 1991; 5: 967-72.Kirch W, Hutt H.J, Plänitz V. The influence of renal function on clinical pharmacokinetics of moxonidine. Clin Pharmacokinet 1988; 15: 245-53.Kirch W, Hutt H.J, Plänitz V. The influence of renal function on clinical pharmacokinetics of moxonidine. Clin Pharmacokinet 1988; 15: 245-53.Krespi P.G Moxonidine effect on microalbuminuria, thrombomodulin, and plasminogen activator inhibitor-1 levels in patients with essential hypertension. Cardiovasc Drugs Ther 1998; 12 (5): 463-7.Krespi P.G Moxonidine effect on microalbuminuria, thrombomodulin, and plasminogen activator inhibitor-1 levels in patients with essential hypertension. Cardiovasc Drugs Ther 1998; 12 (5): 463-7.Schachter M, Mitchell G, Nizol C et al. Antihipertensive efficacy of moxonidine in primary care: a «REAL-LIFE» study. Int J Clin Pract 2003; 57 (6): 479-82.Schachter M, Mitchell G, Nizol C et al. Antihipertensive efficacy of moxonidine in primary care: a «REAL-LIFE» study. Int J Clin Pract 2003; 57 (6): 479-82.Schwarz W, Kandziora J. Long - term experiences with moxonidine, a new antihypertensive. Fortsch Med 1990; 32: 616-20.Schwarz W, Kandziora J. Long - term experiences with moxonidine, a new antihypertensive. Fortsch Med 1990; 32: 616-20.Prichard B.N.C, Küster L.J, Hughes P.R et al. Dose relation of blood pressure reduction with moxonidine findings from three placebo - and active - comntrolled randomized studies. J Clin Basic Cardiol 2003; 6: 49-51.Prichard B.N.C, Küster L.J, Hughes P.R et al. Dose relation of blood pressure reduction with moxonidine findings from three placebo - and active - comntrolled randomized studies. J Clin Basic Cardiol 2003; 6: 49-51.Sanjuliani A.E, Genelhu de Abreu V, Ueleres Braga J, Francischetti E.A. Effects of moxonidine on the sympathetic nervous system, blood pressure, plasma renin activity, plasma aldosterone, leptin and metabolic profile in obese hypertensive patients. J Clin Basic Cardial 2004; 7: 19-25.Sanjuliani A.E, Genelhu de Abreu V, Ueleres Braga J, Francischetti E.A. Effects of moxonidine on the sympathetic nervous system, blood pressure, plasma renin activity, plasma aldosterone, leptin and metabolic profile in obese hypertensive patients. J Clin Basic Cardial 2004; 7: 19-25.Chazova I, Schlaich M.P. Improved Hypertension Control with the Imidazoline Agonist Moxonidine in a Multinational Metabolic Syndrome Population: Principal Results of the MERSY Study. Int J Hypertens 2013; 2013: 541689.Chazova I, Schlaich M.P. Improved Hypertension Control with the Imidazoline Agonist Moxonidine in a Multinational Metabolic Syndrome Population: Principal Results of the MERSY Study. Int J Hypertens 2013; 2013: 541689.Deftereos S et al. Effectiveness of moxonidine to reduce atrial fibrillation burden in hypertensive patients. Am J Cardiol 2013; 112 (5): 684-7.Deftereos S et al. Effectiveness of moxonidine to reduce atrial fibrillation burden in hypertensive patients. Am J Cardiol 2013; 112 (5): 684-7.Krupicka J et al. The efficacy and safety of moxonidine in patients with metabolic syndrome (the O.B.E.Z.I.T.A. trial). [Article in Czech] Vnitr Lek 2011; 57 (6): 541-5.Krupicka J et al. The efficacy and safety of moxonidine in patients with metabolic syndrome (the O.B.E.Z.I.T.A. trial). [Article in Czech] Vnitr Lek 2011; 57 (6): 541-5.

The authors declare that there are no conflicts of interest present.